StockData
Beam Therapeutics Inc. logo

Beam Therapeutics Inc. (BEAM) stock

BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)

Close on Nov 13, 2026Market cap $2.36BP/E –Yield –

Beam Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Beam Therapeutics's enterprise value was $1.57B on Nov 11, 2026, against $1.47B a year earlier. Over the last 5 years it ranged from $391.82M to $4.46B, with a median of $1.35B.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$1.57B-8.4%
2025Dec 31, 2025$1.71B+52.4%
2024Dec 31, 2024$1.12B-3.4%
2023Dec 29, 2023$1.16B-29.9%
2022Dec 30, 2022$1.66B-62.9%
2021Dec 31, 2021$4.46B+14.0%
2020Dec 31, 2020$3.92B–

More Beam Therapeutics figures

See a number that looks wrong?